Release Date: June 20, 2015 | Expiration Date: June 20, 2016
Media: Print with online posttest, evaluation, and request for credit
OverviewThis activity is designed to aid physicians in assessing the use of PARP inhibitors for ovarian cancer and for referrals for clinical trials for breast cancer, including patient-specific treatment regimens and monitoring for adverse events during therapy, and applying these data to their practices.
Instructions For This Activity & Receiving Credit
This activity is directed toward medical oncologists who manage and treat patients with breast and ovarian cancer. Surgical oncologists, radiation oncologists, pathologists, fellows, nurses, nurse practitioners, physician assistants, and other healthcare providers interested in the treatment of breast and ovarian cancer are also invited to participate.
Learning ObjectivesAfter participating in this CME activity, learners should be better prepared to:
- List the role of the PARP enzymes in the cell
- Describe the rationale for PARP inhibition as an investigational treatment for tumors with BRCA mutations
- Describe the rationale for PARP inhibition in the treatment of tumors without BRCA mutations
- Identify PARP inhibitors that are in late-stage development for the treatment of ovarian and breast cancer
Allison A. Muller, PharmD, DABAT
Disclosure: No relevant financial relationships with commercial interests to disclose.
The American Journal of Hematology/ Oncology® Editorial Board
Debu Tripathy, MD
Professor of Medicine and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Disclosure: Grant/research support from Genentech/Roche, Pfizer, Puma Inc, and Novartis (clinical trial support contracted to the University of Southern California and MD Anderson Cancer Center); consultant for Eisai, Oncoplex Diagnostics, Merck, and Novartis.
Myron Czuczman, MD
Professor of Oncology
Chief, Lymphoma/Myeloma Service
Department of Medicine
Head, Lymphoma Translational Research Laboratory
Department of Immunology
Roswell Park Cancer Institute
Disclosure: Other support: advisory board: Algeta, Celgene Corporation, Teva Pharmaceuticals, Boehringer Ingelheim, Mundipharma
FacultyMaurie Markman, MD
President, Medicine & Science
Cancer Treatment Centers of America
Disclosure: Consultant: Celgene Corporation, Amgen, Novartis, Genentech, Takeda Pharmaceuticals
Staff/Planner Disclosures and Conflict of Interest Resolution
The staff of Physicians' Education Resource (PER®), LLC (Ann C. Lichti, CHCP, Michael Perlmutter, PharmD, MS, and Kerry Clayton) as well as the editorial staff of The American Journal of Hematology/Oncology (Devera Pine) have no relevant financial relationships with commercial interests to disclose.
In accordance with Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial SupportSM, PER® resolved all conflicts of interest (COI) prior to the release of this CME activity using a multistep process.
Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is funded by Physicians' Education Resource®.
Off-Label Disclosure and Disclaimer
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
DisclaimerThe opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.
Hardware And Software RequirementsSupported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)
Minimum System Requirements (Windows)
- A Pentium-based PC or compatible computer
- At least 64MB of RAM
- Windows 95/98/NT/ME/2000/XP/Vista system software
- Screen resolution of 1024 x 786 or larger recommended
- PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise